Addex Therapeutics
ADXN
3 hedge funds and large institutions have $717K invested in Addex Therapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
15% more capital invested
Capital invested by funds: $625K → $717K (+$91.7K)
0.06% more ownership
Funds ownership: 0.03% → 0.09% (+0.06%)
40% less funds holding
Funds holding: 5 → 3 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$101K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
-$6.58K |
| 2 |
Jane Street
New York
|
-$4.07K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$28 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NMC
1
NEA Management Company
Timonium,
Maryland
| $306K | – | – | – |
|
|
AC
2
Armistice Capital
New York
| $260K | +$101K | +16,150 | +60% |
|
|
JSC
3
J. Stern & Co
London,
United Kingdom
| $151K | +$677K | +107,827 | New |
|
|
BBA
4
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| – | -$6.58K | -960 | Closed |
|
|
5
Jane Street
New York
| – | -$4.07K | -529 | Closed |
|
|
6
UBS Group
Zurich,
Switzerland
| – | -$28 | -4 | Closed |
|
ADXN Hedge Fund Activity: Q4 2023 in Review
3 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q4 2023, worth a combined $717K — up 15% from $625K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ADXN and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Armistice Capital, adding an estimated $101K. The largest seller was Baader Bank Aktiengesellschaft, exiting entirely with an estimated $6.58K sold.
- 3 institutional investors held Addex Therapeutics (ADXN) as of Q4 2023, down from 5 in Q3 2023.
- Funds reported $717K of Addex Therapeutics stock for Q4 2023, up 15% quarter-over-quarter.
- 1 fund opened new Addex Therapeutics positions in Q4 2023 and 3 closed out, a net change of -2 holders.
- The largest Addex Therapeutics buyer in Q4 2023 was Armistice Capital, an estimated $101K added.
- The largest Addex Therapeutics seller in Q4 2023 was Baader Bank Aktiengesellschaft, an estimated $6.58K sold.
Based on aggregated 13F filings for Q4 2023.